T-DXd with pyrotinib for first-line HER2-positive metastatic breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Pyrotinib, as a first treatment for HER2-positive breast cancer that has spread or cannot be removed. It aims to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your breast cancer must be HER2-positive (a protein that helps cancer grow) and have spread to other parts of the body (metastatic) or cannot be removed by surgery.
- You must not have had chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer before, unless you only had one line of hormone therapy.
- You must be well enough to carry out daily activities (ECOG score 0-1) and have a life expectancy of at least 12 weeks.
- You must have healthy organs, including heart, lungs, liver, kidneys, and bone marrow, as shown by blood tests and scans.
- You must not have serious lung problems, a history of interstitial lung disease, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.